Learn about Clostridium difficile infection (CDI, C. difficile infection) diagnosis, including clinical documentation and medical coding for healthcare professionals. Find information on Clostridioides difficile infection symptoms, testing, and treatment guidelines. This resource supports accurate CDI diagnosis coding and complete clinical documentation for optimal patient care and reimbursement.
Also known as
Enterocolitis due to Clostridium difficile
Infection of the intestines caused by C. difficile bacteria.
Intestinal infectious diseases
Diseases caused by bacterial, viral, or parasitic infections of the intestines.
Other specified noninfective gastroenteritis and colitis
Gastrointestinal inflammation not caused by infection, including antibiotic-associated colitis which can be a consequence of C.difficile.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the C. difficile infection associated with antibiotic use?
When to use each related code
| Description |
|---|
| Infection causing diarrhea and colitis. |
| Inflammation of the colon, not from C. difficile. |
| Antibiotic-associated diarrhea, C. difficile negative. |
Coding C. difficile infection without specifying whether it's initial or recurrent can lead to inaccurate reimbursement and quality reporting.
Overlooking documentation suggesting CDI, especially in patients with diarrhea after antibiotic use, can impact patient safety and CDI tracking.
Miscoding present on admission (POA) status for CDI can affect hospital-acquired infection reporting and reimbursement.
Q: What are the most effective Clostridium difficile infection treatment guidelines for recurrent CDI in hospitalized adults?
A: Recurrent Clostridium difficile infection (CDI) poses a significant challenge in hospitalized adults. Current treatment guidelines emphasize a staged approach based on recurrence severity and history. For a first recurrence, fidaxomicin or a pulsed-tapered vancomycin regimen is often recommended. For subsequent recurrences, bezlotoxumab, a monoclonal antibody targeting C. difficile toxin B, may be considered, along with fecal microbiota transplantation (FMT). Successful management of recurrent CDI requires careful consideration of antibiotic stewardship principles to minimize further disruption of the gut microbiota. Explore how implementing a robust antimicrobial stewardship program can reduce CDI recurrence rates in your hospital setting.
Q: How can I differentiate between Clostridioides difficile infection (CDI) and other causes of antibiotic-associated diarrhea in my patients?
A: Differentiating Clostridioides difficile infection (CDI, previously known as C. difficile infection) from other causes of antibiotic-associated diarrhea (AAD) requires a multi-faceted approach. While AAD can result from various factors including antibiotic-induced changes in gut flora, CDI is specifically caused by the toxins produced by C. difficile. Clinical presentation can be similar, with symptoms ranging from mild diarrhea to severe colitis. However, the presence of leukocytosis, abdominal pain, and a history of recent antibiotic use should raise suspicion for CDI. Definitive diagnosis relies on laboratory testing, including stool tests for C. difficile toxins. Consider implementing a diagnostic algorithm that incorporates both clinical and laboratory findings to accurately identify CDI and differentiate it from other causes of AAD. Learn more about the latest diagnostic tests for C. difficile infection and their clinical utility.
Patient presents with symptoms consistent with Clostridium difficile infection (CDI, C. difficile infection), including frequent watery diarrhea, abdominal pain, and cramping. The patient reports experiencing more than three loose stools within a 24-hour period for the past two days. Fever and nausea are also present. Recent antibiotic use of clindamycin within the past six weeks is documented. Physical examination reveals mild lower abdominal tenderness. Given the clinical presentation and risk factors, Clostridioides difficile infection is suspected. Stool studies for C. difficile toxin are ordered to confirm the diagnosis. Initial treatment plan includes oral vancomycin and discontinuation of the current antibiotic regimen. The patient is advised on infection control measures, including hand hygiene and contact precautions. Differential diagnosis includes other causes of infectious diarrhea such as bacterial gastroenteritis, viral gastroenteritis, and antibiotic-associated diarrhea. Patient education regarding the course of CDI, potential complications including pseudomembranous colitis, and recurrence prevention strategies will be provided. Monitoring for clinical improvement and response to therapy will continue. ICD-10 code A04.7 will be used for Clostridium difficile colitis, and additional codes may be added based on severity and complications. Appropriate medical billing codes will be applied based on the provided services and procedures performed.